Pre-Market Analysis: Inovio Pharmaceuticals Inc., Sequenom Inc., and Optimer Pharmaceuticals Inc.
LONDON, October 4, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
The U.S. equity markets declined on Thursday, October 03, 2013, with the S&P 500, the Dow Jones Industrial Average, and the NASDAQ Composite falling by 0.90%, 0.90%, and 1.07%, respectively. Shares in the biotechnology industry ended on a mixed note, even as the broader market posted losses. The major movers in the industry included Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Sequenom Inc. (NASDAQ: SQNM), and Optimer Pharmaceuticals Inc. (NASDAQ: OPTR). All these companies are tracked by AAAResearchReports.com. Free technical research on INO, SQNM, and OPTR can be downloaded upon signing up at:
Shares in Inovio Pharmaceuticals Inc. ended flat on Thursday, even as the broader market posted losses. The company's shares closed the day at the previous day's closing price of $2.08, after oscillating between $2.05 and $2.12 during the trading session. A total of 2.58 million shares were traded, which is significantly below the daily average volume of 10.37 million. The company's shares have surged 8.33% in the last one month and 144.71% in the previous three months, outperforming the S&P 500 which has advanced 2.37% and 3.92% during the respective periods. Furthermore, Inovio Pharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages of $1.99 and $1.16, respectively. Sign up and read the complimentary report on INO at:
Sequenom Inc.'s stock fell by 0.37% on Thursday, tracking losses in the broader market. The company's shares traded between $2.64 and $2.75 before finishing the day at $2.66. A total of 1.87 million shares were traded, which is below the daily average volume of 3.26 million. Sequenom Inc.'s shares have declined by 10.74% in the last one month, underperforming the S&P 500 which has gained 2.37% during the same period. Additionally, the company's stock is trading below its 50-day and 200-day moving averages of $2.89 and $3.70, respectively. The free report on SQNM can be downloaded by signing up now at:
On Thursday, shares in Optimer Pharmaceuticals Inc. fell by 0.39%, reversing all of the gains from the previous trading session. The company's shares closed the day at $12.62, after fluctuating between $12.56 and $12.70. A total of 0.75 million shares were traded, which is below the daily average volume of 1.24 million. Despite Thursday's losses, the company's shares have advanced 0.24% in the previous three trading sessions and 0.64% in the last one month, compared to a loss 0.17% and a gain of 2.37% in the S&P 500 during the respective periods. Moreover, Optimer Pharmaceuticals Inc.'s stock is trading above its 50-day moving average of $12.61. Register with AAA Research Reports and download research on OPTR for free at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports